Phase 2 N=86 E3-Hormone Refractory Prostrate Cancer Taxotere Combination
Prostate Cancer · Metastatic · Hormone Refractory
Primary: Prostate Specific Antigen (PSA) Response — 17; 29 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
Thyroid Cancer
Primary: Objective Response Rate — 6 Participants
Phase 2 N=106 A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients
Colorectal Cancer
Primary: Number of Patients With an Objective Disease Progression Event — 20; 24; 24 Participants
Phase 2 N=64 E3 Breast Cancer Taxotere Combination
Advanced Breast Cancer
Primary: Number of Patients With a Disease Progression Event — 24; 18 Participants
Phase 2 N=104 A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer
Colorectal · Cancer
Primary: Number of Patients With an Objective Disease Progression Event — 23; 27; 24 Participants
Phase 2 N=39 Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC
Lung Cancer
Primary: Number of Participants Whose Response Allowed Them to Proceed to Chemoradiation — 38 participants
Phase 2 N=96 A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
Neuralgia, Postherpetic
Primary: Change From Baseline in the Mean 24-hour Average Pain Intensity (API) Score at the Last Week of Each Treatment Period Using Last Observation Carried Forward (LOCF) Data…
Phase 2 N=376 A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)
Neuralgia, Postherpetic
Primary: Change From Baseline in the Mean 24-hour Average Pain Intensity (API) Score at the End of Maintenance Treatment (EOMT) Using Last Observation Carried Forward (LOCF) Data…
Phase 2 N=135 Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer
Breast Cancer
Primary: Tumor Response Rate — 26.6; 29.5; 0.0; 3.3 percentage of participants
Phase 2 N=424 AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)
Anxiety Disorders
Primary: Change From Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score — -10.9; -11.1; -11.5; -10.9 Units on scale
Phase 2 N=98 Safety and Tolerability Study of Drug to Treat Schizophrenia
Schizophrenia
Primary: Number of Participants With Adverse Events — 19; 22; 18 participants
Phase 2 N=49 Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis
Iron Overload · Hereditary Hemochromatosis
Primary: Absolute Change of Serum Ferritin From Baseline to the End of Extension, by Dose Cohort (Extension Per-protocol Population) — -389.1; -610.5; -571.6 µg/L
Phase 2 N=226 A Study of the Efficacy and Safety of Amitriptyline/Ketamine Topical Cream in Patients With Diabetic Peripheral Neuropathy
Diabetic Peripheral Neuropathy · Neuralgia
Primary: Placebo vs. Active Comparison of the Change From Average Pain at Baseline to Average Pain at 4 Weeks. — 1.64; 2.12 units on a scale — p=0.083
Phase 2 N=109 Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: The Number of Chromosomal Aberrations Per 100 Cells Excluding Gaps at Baseline and at the End of Treatment i.e Day 84 (Week 12) — 1.05; 0.75; 0.53; 0.41 number of…
Phase 2 N=40 Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder
Depressive Disorder, Major Depressive Disorder
Primary: Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs) — 13; 15; 1; 0 participants